Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 10, showing 5 Applications out of 50 total, starting on record 11, ending on 15

# Protocol No Study Title Investigator(s) & Site(s)

11.

ECCT/22/04/02   GO42144
    A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS        
Principal Investigator(s)
1. Mansoor Noorali Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View

12.

ECCT/22/03/03   HVTN 140/HPTN 101
        A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants_HVTN 140/HPTN 101       
Principal Investigator(s)
1. Josphat kosgei
Site(s) in Kenya
KEMRI WRP, KERICHO
 
View

13.

ECCT/22/03/01   The \"NOVATION-1\" Trial
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19   
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. KEMRI Kericho (Kericho county)
4. KEMRI Siaya (Kisumu county)
5. Kenyatta National Hospital (Nairobi City county)
 
View

14.

ECCT/21/03/05   Unithiol Phase I
    TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming Phase 1 (Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Kenyan Adults)   
Principal Investigator(s)
1. Michael Abouyannis
2. Mainga Patience Mayeso Hamaluba
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
View

15.

ECCT/20/11/02   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing  Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and   African Adults (IAVI C100)   
Principal Investigator(s)
1. Nelly Mugo
Site(s) in Kenya
1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county)
2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county)
 
View